ALPEGA-GROUP
13.2.2020 17:07:04 CET | Business Wire | Press release
Teleroute, Europe’s leading freight exchange, has announced the launch of Payment Guarantee for carriers. This unique, new service ensures carriers are protected in case of non-payment and is part of Teleroute’s vision to build a truly collaborative network for the transportation industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005649/en/
Teleroute has partnered with Coface, a worldwide leader in credit insurance, to offer a solution that allows carriers to ensure payment for any transport executed using its freight exchange.
Speaking on the launch of Payment Guarantee, Alpega’s Chief Operating Officer, Fabrice Douteaud, said: “Teleroute is Europe’s largest freight and vehicle exchange for domestic and international routes and offers countless opportunities for carriers. However, we know it can be stressful to work with a freight forwarder you know little about, which is why we developed Payment Guarantee. This new service is unique to the market and means carriers can take advantage of the lucrative offers out there, without having to worry about being paid. It’s a great way to open up the market and help businesses make the most of the opportunities out there.”
Carriers can register for Payment Guarantee online, on a case-by-case basis, and receive instant feedback regarding cost and coverage. The ability to guarantee payment for any given transport allows carriers to price their services more competitively and effectively cut costs for shippers and freight forwarders.
Wtransnet, the leading freight exchange in Iberia, has been offering the Payment Guarantee service for more than 15 years and it is one of the solution’s most popular features. Wtransnet became part of the Alpega Group in 2018 and, alongside similar initiatives with Bursa and 123Cargo, the leading freight exchange in Romania, this project illustrates the drive to adapt best practice from across the industry.
The launch of Payment Guarantee sees Teleroute consolidate its position as Europe’s leading freight exchange and highlights its goal of building a truly collaborative transportation network.
In addition to solving spot needs, Teleroute provides more than 70.000 transport companies with significant added value in their day-to-day activities, through its smart and easy to use platform that publishes supply and load demands in real-time.
About Alpega
The Alpega Group is a leading global logistics software company offering end-to-end solutions that cover all transportation needs, including Transport Management Systems (TMS) and Freight Exchanges. The Transport Management Systems (TMS) software solutions – inet and Transwide– connect companies to a broad network of logistics providers and digitize their complex supply chain management. These systems provide live visibility of incoming and outgoing logistics and seamlessly link truck drivers and logistics providers with shippers. The freight exchanges – Teleroute, Wtransnet, Bursa and 123cargo – serve as marketplaces for matching spot shipments and capacities. TenderEasy, for its part, allows shippers to easily send e-tenders to the carrier community. All of the above solutions can be combined to create more added value for customers. Our user community of 80.000 carriers and shippers and 200.000 members are electronically connected every day to successfully manage critical transport processes of 108.000.000 orders every year. Alpega is present in 80 countries worldwide and employs over 500 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005649/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom